{"links":{"html":"https://www.erudio.com/reports/dawn-303-nct07522073","json":"https://www.erudio.com/reports/dawn-303-nct07522073.json","markdown":"https://www.erudio.com/reports/dawn-303-nct07522073.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"dawn-303-07522073"}},"request":"https://www.erudio.com/contact?report=dawn-303-07522073"},"offer":{"cited_commentary_sources":15,"verified_hcp_statements":58,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":9,"optional":true,"price_per_verified_person_usd":15,"price_usd":135,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"dawn-303-nct07522073"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=dawn-303-07522073","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/dawn-303-nct07522073","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T02:10:27.098549Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":1},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Overall Survival (OS)"},{"claim_count":1,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":1,"title":"Primary endpoint: Progression-free survival (PFS) by BICR"},{"claim_count":7,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":6,"title":"Primary endpoint: Objective Response by BICR"},{"claim_count":3,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.secondaryOutcomes","source_count":3,"title":"Secondary endpoints"},{"claim_count":4,"coverage":"discussed","id":"T5","registry_field":"conditionsModule","source_count":2,"title":"Population and setting"},{"claim_count":12,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.armGroups","source_count":8,"title":"The comparison"},{"claim_count":11,"coverage":"discussed","id":"T7","registry_field":"outcomesModule","source_count":6,"title":"Safety and tolerability"},{"claim_count":5,"coverage":"discussed","id":"T8","registry_field":"designModule","source_count":2,"title":"Design and conduct"},{"claim_count":14,"coverage":"discussed","id":"A1","source_count":1,"title":"Timely molecular work-up and access to an upfront trial choice"},{"claim_count":7,"coverage":"discussed","id":"A2","source_count":3,"title":"Conditional frontline placement, maintenance and unresolved sequencing"},{"claim_count":10,"coverage":"discussed","id":"A3","source_count":9,"title":"Response benchmarks and the strength of inference"},{"claim_count":7,"coverage":"discussed","id":"A4","source_count":1,"title":"Fitness, preferences and the option not to intensify treatment"}],"counts":{"cited_sources":15,"claims_by_expression_type":{"comparison":8,"experience":1,"interpretation":13,"opinion":24,"primary_context":1,"question":2,"restatement":7,"unspecified":2},"claims_by_kind":{"attributed_opinion":15,"source_observation":43},"clinician_statements":25,"evidence_units":41,"findings":5,"organisational_accounts":2,"people_cited":11,"people_identity_verified":9,"people_total":11,"screened_sources":43,"verified_claims":58},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":11,"claims_by_group":{"comparisons":5,"experience":1,"questions":0,"restated":0,"views":5},"has_counterview":true,"limitations":3,"links":{"context":0,"support":11},"ma_question":true,"named_voices":6,"passages":8,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"Selectivity-based safety confidence is qualified by a specific GI-toxicity concern"},{"id":"F2","structure":{"claims":10,"claims_by_group":{"comparisons":2,"experience":1,"questions":0,"restated":1,"views":6},"has_counterview":true,"limitations":5,"links":{"context":0,"support":12},"ma_question":true,"named_voices":8,"passages":10,"sources":9,"sources_by_kind":{"commentary":8,"media":1}},"title":"Response enthusiasm supports further evaluation, not comparative efficacy conclusions"},{"id":"F3","structure":{"claims":10,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":2,"views":5},"has_counterview":false,"limitations":3,"links":{"context":0,"support":13},"ma_question":true,"named_voices":2,"passages":7,"sources":2,"sources_by_kind":{"media":2}},"title":"The proposed future is a conditional add-on strategy, with chemotherapy withdrawal tied to chemotherapy toxicity"},{"id":"F4","structure":{"claims":15,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":3,"views":11},"has_counterview":false,"limitations":3,"links":{"context":0,"support":15},"ma_question":true,"named_voices":2,"passages":9,"sources":2,"sources_by_kind":{"media":2}},"title":"Molecular information must arrive before the frontline decision to create a meaningful trial option"},{"id":"F5","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":5},"has_counterview":false,"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":1,"passages":4,"sources":1,"sources_by_kind":{"media":1}},"title":"Frontline intensification is not the only decision: fitness, preferences and supportive care remain consequential"}],"medical_affairs_question":"How should Medical Affairs discuss early response enthusiasm, GI burden and timely testing without implying proven survival benefit, a preferred backbone or established maintenance practice?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Selectivity does not settle the combination's treatment burden"},{"id":"section-2","level":2,"title":"Response enthusiasm is strongest as a rationale for testing the add-on"},{"id":"section-3","level":2,"title":"Add-on positioning and maintenance remain conditional proposals"},{"id":"section-4","level":2,"title":"An upfront trial option depends on an upfront molecular result"},{"id":"section-5","level":2,"title":"Fitness and patient priorities can favor withholding rather than adding treatment"},{"id":"section-6","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Overall Survival (OS)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1}],"id":"T2","label":"Primary endpoint: Progression-free survival (PFS) by BICR"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":7}],"id":"T3","label":"Primary endpoint: Objective Response by BICR"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1}],"id":"T4","label":"Secondary endpoints"},{"findings":[{"id":"F4","shared_claims":4}],"id":"T5","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":6},{"id":"F3","shared_claims":4}],"id":"T6","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":10},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":2}],"id":"T7","label":"Safety and tolerability"},{"findings":[{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":1}],"id":"T8","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T02:10:27.098549Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T02:31:58Z","record_hash":"4053091e89201c835feb07f42a08aa6ee538cad3fc57cc48a0927fe61463076d","release_hash":"db81cc77d496cbba8d14a9cd38d602bf6432c675cca0e5bf5d7e3761fd71421c","report_id":"erudio-nct07522073","run_id":"15c435e4-0ef8-41cd-be09-b380eef25e0b","schema_version":"5.0","slug":"dawn-303-07522073","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"DAWN-303 tests whether adding INCB161734 to first-line chemotherapy improves outcomes in untreated KRAS G12D-mutated metastatic pancreatic cancer. A podcast guest who reports involvement in INCB161734’s phase 1 development frames future add-on use as conditional. Speakers welcome response activity, while gastrointestinal tolerability draws concern from a social-media account whose identity and clinical role are not established in the sources reviewed for this edition. How to combine and sequence treatments remains an open question in a presentation.","meta_description":"43 sources screened · 58 verified statements (25 from clinicians verified by NPI or staff page) from 15 sources · 5 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-da297ace10c5eb9ef52f"],"id":"F3","paraphrase":"A podcast interview addresses whether DAWN-303 needs a treatment arm using INCB161734 alone.","publication_caveats":["The guest reports involvement in INCB161734’s phase 1 development.","The rationale for omitting a monotherapy arm is the guest’s explanation, not an independently documented protocol instruction."],"source_channel":"podcast","source_date":"2026-09-23","title":"The proposed future is a conditional add-on strategy, with chemotherapy withdrawal tied to chemotherapy toxicity"},{"cited_claim_ids":["claim-b088ec16ac4366dbf91a"],"id":"F4","paraphrase":"A YouTube presentation asks how treatment options might differ if a KRAS G12D result were available before initial chemotherapy.","publication_caveats":["The presentation does not identify who asks this question.","The discussion does not establish any individual patient’s eligibility for DAWN-303."],"source_channel":"youtube","source_date":"2026-07-14","title":"Molecular information must arrive before the frontline decision to create a meaningful trial option"}]},"publication":{"approved_at":"2026-10-29T02:31:58Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":43},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on response durability with targeted therapy plus chemotherapy in pancreatic cancer.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","85 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","This report represents the sources reviewed for this edition, not all HCPs or public discussion. Unnamed references and variant trial or drug spellings may be missed.","Some earlier-phase discussions, several organization-authored trial announcements and part of the PeerView presentation were not fully assessed for their relevance to the frontline decision. Absence from this report is not evidence that no additional views exist.","No exact-trial results publication or full protocol is included. Product-label documentation for the interventions is also absent; the report supports no conclusion about approval status.","Early monotherapy, previously treated and combination findings must not be treated as outcomes in DAWN-303's previously untreated population.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Unattributed PeerView passages may be from a named participant, but their speaker cannot be identified from the available evidence. They are not additional independent voices.","Repeated posts, reposts and quoted earlier posts do not establish independent assessments or consensus. Publication and post dates do not establish session dates, readout dates or changes of mind."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":1,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":11,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":15},"count":15,"evidence_window":{"end":"2026-10-26","start":"2026-01-09"},"retrieval_snapshot":"2026-10-28T22:08:01.451627Z","timeline":[{"count":1,"week":"2026-W02"},{"count":3,"week":"2026-W25"},{"count":1,"week":"2026-W29"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W42"},{"count":8,"week":"2026-W44"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT07522073:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07522073:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-47eyg4sm7lvqbke5glkahofa-3mys6jl5dac22","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-47eyg4sm7lvqbke5glkahofa-3mys6kshixc22","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3mu5vobub4222","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3muhxayxypc2b","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3mvqf7zftb22j","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3mw2o5c3vvc22","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-hvybly7ak5rfumcoeda5r4mx-3mbzc4l55xc2x","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-qfkt3i5kooppuue5onesacut-3mw66dapxr226","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7516151977169485826","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:83f79f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009672231769772279:72363bd2-3044-49df-abe9-15f62a77e452","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009802575391109556:a3eeb55f-0b90-44ef-85b2-8cba22870705","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061188946999284115:eec8829f-f193-4009-b96b-3713d292f37d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061812896883949707:7f4be7ca-7d63-42a3-9411-ae91a486b167","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2062249723394732035:d4eacd91-44c3-40f5-9268-ac11d46d30e5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2066601601645830419:058d1810-955f-4252-a298-f797503d8d49","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2066601823335772382:d1565039-1980-47b3-9f1c-3b46441507fc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2066601913223897596:a5d4cb1c-d9c9-40de-9700-359dd124521d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2066602249644814396:52ded536-d162-436c-82c6-1673d75fd617","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2093392365763367342:85d8c32e-23d2-4a76-a58e-4372d3bcfcd0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2093392620974133740:e49e6057-61c9-4bbc-aa53-d9470a55558f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094808132903989680:0b47ad63-b065-44a8-a7b6-265627a27990","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099467620026044824:fe94b6c2-0fa6-4e35-b685-20210ac6823c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100332958947151946:3a985f60-54a9-4854-978d-e7b9e5f26d8b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100668127881429452:81bb6bc9-168a-4c2d-8a39-4bcb7cc19042","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100872457951625454:edcdbbc7-503c-44ee-96f8-f427007c1303","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100926032945766463:efe15172-f93d-46fe-9608-23eed55535b1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102149561959567650:5d41e603-3b23-4805-bf89-1be71390be2a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102818156100338026:9b2680f0-8792-4daa-b410-931c788e6aa9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103531069295202396:d86aab6e-0885-4dad-9e37-c9e482d297b1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103534594750586926:40696ec4-fd2a-4283-8826-c2d95bf79c89","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108692858203255030:c30de3ab-b6bd-4c0e-b684-35409ef5dfe5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108747082454417422:8264cadd-3df7-4920-a82f-2c4e18375c5e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112499079972331890:85a045d7-a931-4a9b-901d-2f9a33e6c62f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114718704906785016:fcd601d4-3622-470d-9923-8c00cbd6c8b8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114719147120546037:6a2f4ecd-c2a5-4579-a5fe-f390ae470774","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114722228151460020:cadd3d63-fed3-4c39-9d8c-07d365e64362","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114722312222015894:5bd38202-f6be-4356-814d-47a655bba630","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114722545585045603:d44d4b6b-4562-4e07-9f3d-a75361b094c5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114724395545731428:366f4dac-ba5e-42d8-ac35-03f6e23a7970","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114732513184870830:617cf7ba-4a83-44ad-b0af-efa2248b131d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114748697938448671:eb473774-8bec-4f39-80ca-47a9e3d5c37d","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:E3IKyMc1ZdE","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":8,"linkedin_post":1,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":32,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":43},"count":43,"evidence_window":{"end":"2026-10-26","start":"2026-01-09"},"retrieval_snapshot":"2026-10-28T22:08:01.451627Z","timeline":[{"count":3,"week":"2026-W02"},{"count":1,"week":"2026-W22"},{"count":2,"week":"2026-W23"},{"count":4,"week":"2026-W25"},{"count":1,"week":"2026-W29"},{"count":3,"week":"2026-W35"},{"count":2,"week":"2026-W36"},{"count":6,"week":"2026-W38"},{"count":7,"week":"2026-W39"},{"count":2,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":1,"week":"2026-W43"},{"count":10,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: incb161734","status":"unmapped"},{"reason":"Unmapped registry intervention: investigator's choice of chemotherapy","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Solid Tumors","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"DAWN-303","aliases":["DAWN-303","A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma","A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)"],"brief_title":"A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma","collaborators":["Qiagen Manchester Ltd"],"conditions":["Solid Tumors"],"enrollment":{"count":588,"type":"ESTIMATED"},"interventions":[{"name":"INCB161734","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Placebo","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Investigator's choice of chemotherapy","synonyms":["mFOLFIRINOX","GemNabP"],"type":"DRUG"}],"nct_id":"NCT07522073","official_title":"A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2028-09-15","type":"ESTIMATED"},"primary_endpoints":[{"description":"Defined as the time from the date of randomization to the date of death due to any cause.","measure":"Overall Survival (OS)","timeFrame":"Up to approximately 3 years"},{"description":"Defined as the time from the date of randomization to the date of the first documented progression as determined by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death due to any cause.","measure":"Progression-free survival (PFS) by BICR","timeFrame":"Up to approximately 2 years"},{"description":"Defined as complete response (CR) or partial response (PR) as determined by BICR per RECIST v1.1.","measure":"Objective Response by BICR","timeFrame":"Up to approximately 2 years"}],"registry_last_updated":"2026-10-08","registry_url":"https://clinicaltrials.gov/study/NCT07522073","short_name":"DAWN-303","short_name_basis":"registry_acronym","sponsor":"Incyte Corporation","start_date":{"date":"2026-04-09","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"INCB161734-303","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}